MEI Pharma (MEIP) – Business Wire
-
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
-
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
-
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
-
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
-
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
-
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
-
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
-
MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights
-
MEI Pharma to Present at the Stifel 2023 Healthcare Conference
-
MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock
-
MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023
-
MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital
-
MEI Pharma Recommends Stockholders Not to Consent
-
MEI Pharma Adopts Limited-Duration Stockholder Rights Plan
-
MEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic Actions
-
MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights
-
MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023
-
MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car
-
MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer
-
MEI Pharma Announces Results of Special Meeting of Stockholders
-
MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction
-
MEI Pharma Responds to Anson and Cable Car
-
MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction
-
MEI Pharma Postpones Special Meeting of Shareholders
-
MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals
-
MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals
-
ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.
-
MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals
-
MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals
-
MEI Pharma Responds to Anson and Cable Car
-
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
-
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
-
MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor
-
MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor
-
MEI Pharma Board of Directors Rejects Unsolicited Proposal
-
MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal
-
MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies
-
MEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational Highlights
-
MEI Pharma Announces 1-for-20 Reverse Stock Split
-
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates
-
MEI Pharma Reports Second Quarter Fiscal Year 2023 Results and Operational Highlights
-
MEI Pharma Announces Adjournment of Annual Meeting of Stockholders
-
MEI Pharma Initiates Strategic Realignment
-
MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
-
Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan
-
MEI Pharma Reports First Quarter Fiscal Year 2023 Results and Operational Highlights
-
MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022
-
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
-
MEI Pharma Announces Changes to Board of Directors
-
MEI Pharma Reports Fiscal Year 2022 Results and Operational Highlights
Back to MEIP Stock Lookup